Susquehanna International Group, LLP Gemini Therapeutics, Inc. Transaction History

Susquehanna International Group, LLP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	BUY	$1.22 - $1.73 $15,090 - $21,398	12,369 Added 74.36%	29,002 $49,000
Q1 2022 May 16, 2022	SELL	$1.29 - $3.08 $38,083 - $90,927	-29,522 Reduced 63.96%	16,633 $23,000
Q4 2021 Feb 14, 2022	SELL	$2.39 - $4.0 $129,483 - $216,708	-54,177 Reduced 54.0%	46,155 $134,000
Q3 2021 Nov 15, 2021	BUY	$3.3 - $6.32 $150,169 - $287,597	45,506 Added 83.0%	100,332 $405,000
Q2 2021 Aug 11, 2021	BUY	$6.32 - $14.02 $72,458 - $160,739	11,465 Added 26.44%	54,826 $355,000
Q1 2021 May 17, 2021	BUY	$11.32 - $18.0 $490,846 - $780,498	43,361 New	43,361 $588,000

2.44M

Ticker GMTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,244,500
Market Cap $1.05B
Description
Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 ...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.